Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex (MHC) class II molecules are cell surface glycoproteins that play a critical role in the adaptive immune response. They are primarily expressed on professional antigen-presenting cells (APCs) and function to present processed peptide antigens derived from exogenous proteins to CD4+ T lymphocytes, thereby initiating and regulating antigen-specific immune responses. MHC class II molecules are heterodimers composed of an α chain and a β chain, both encoded within the MHC locus. These molecules are highly polymorphic, contributing to the diversity of antigen presentation and influencing susceptibility to autoimmune diseases. Deficiencies or mutations affecting MHC class II expression or function can lead to severe immunodeficiencies.
Modulation of antigen presentation to CD4+ T cells (e.g., blocking peptide binding, altering MHC-II expression).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex Molecule Class II (MHC class II).